Project Grant H79TI083182

The Mohegan Tribe of Indians of Connecticut received a 5-year, $1,000,000 Project Grant award from the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program. The award will fund the Mohegan Tribal Opioid Response Project, which aims to increase medication-assisted treatment (MAT) services and provide opioid/stimulant misuse education, prevention, and treatment...

The Stockbridge-Munsee Health and Wellness Center Opioid Response Project is a $373,449 federal grant award funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program. The project aims to increase access to culturally appropriate and evidence-based treatment for opioid use disorder, including medication-assisted treatment using Vivitrol, purchasing and...

The U.S. Department of Health and Human Services Substance Abuse and Mental Health Services Administration (SAMHSA) awarded a $591,268 Project Grant under the Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program to the Eastern Shoshone Tribe's Doya Natsu Healing Center (DNHC). The 5-year grant, effective September 30, 2024, will support the Tribal Opioid Response 4 (TOR4) project. The project aims to: 1) Increase access to...

This federal Project Grant award of $1,151,576 was provided by the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program. Through this 5-year Tribal Opioid Response (TOR) IV project, the Rocky Mountain Tribal Leaders Council (RMTLC) will work with the Little Shell Tribe of Chippewa Indians and Urban Indian Health Centers in Montana to develop a...

The Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program, administered by the Substance Abuse and Mental Health Services Administration (SAMHSA), has awarded a $1,000,000 Project Grant to the Indian Health Council, Inc. (IHC) in Valley Center, CA. The 5-year grant, which commenced on September 30, 2024, will fund a "2024 Tribal Opioid Response" project to serve American Indians in and around nine federally recognized tribes...

This Project Grant award from the U.S. Department of Health and Human Services (DHHS) Substance Abuse and Mental Health Services Administration (SAMHSA) under the Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program provides $341,268 to the Sisseton Wahpeton Oyate tribal government to implement the Tribal Opioid Response Program. The program aims to enhance substance use disorder treatment services, increase access to opioid overdose...

This Project Grant award of $850,000 was provided by the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program. The funding supports the Oneida Nation Tribal Opioid Response Project, a culturally-based, trauma-informed prevention service aimed at addressing the opioid crisis in the Oneida community. Key services include traditional substance abuse counseling,...

This Project Grant award of $1,297,604.00 from the U.S. Department of Health and Human Services (HHS) Substance Abuse and Mental Health Services Administration (SAMHSA) under the Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program will assist the Muscogee (Creek) Nation in Oklahoma in addressing the opioid overdose crisis within their communities. The funding will be used to increase access to FDA-approved medications for the...

This Project Grant award of $2,902,673.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is focused on establishing OPRM1 exon 7-associated variants as novel therapeutic targets to mitigate adverse effects of clinically used mu opioids without altering analgesia in pain management. The research aims to characterize antisense oligonucleotides (ASOs) and rabbit monoclonal antibodies (RABMABs) targeting mouse OPRM1 exon 7...

The Mathiesen Memorial Health Clinic (MMHC) was awarded a $1,000,000 five-year Project Grant (H79TI087796) by the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program. The grant funding will support MMHC's efforts to expand medication-assisted treatment (MAT) and substance use counseling services through its Red Feather Clinic in the rural Sierra Nevada...